Tweet
Anavar and fatloss
Oral anabolic steroid treatment, but not parenteral androgen treatment,
decreases abdominal fat in obese, older men.
Lovejoy JC, Bray GA, Greeson CS, Klemperer M, Morris J, Partington C, Tulley R.
Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808-4124, USA.
OBJECTIVE: To compare the effects of testosterone enanthate (TE), anabolic
steroid (AS) or placebo (PL) on regional fat distribution and health risk
factors in obese middle-aged men undergoing weight loss by dietary means.
DESIGN: Randomized, double-blind, placebo-controlled clinical trial, carried out
for 9 months with primary assessments at 3 month intervals. Due to adverse blood
lipid changes, the AS group was switched from oral oxandrolone (ASOX) to
parenteral nandrolone decaoate (ASND) after the 3 month assessment point.
SUBJECTS: Thirty healthy, obese men, aged 40-60 years, with serum testosterone
(T) levels in the low-normal range (2-5 ng/mL).
MAIN OUTCOME MEASURES: Abdominal fat distribution and thigh muscle volume by CT
scan, body composition by dual energy X-ray absorptiometry (DEXA), insulin
sensitivity by the Minimal Model method, blood lipids, blood chemistry, blood
pressure, thyroid hormones and urological parameters.
RESULTS: After 3 months, there was a significantly greater decrease in
subcutaneous (SQ) abdominal fat in the ASOX group compared to the TE and PL
groups although body weight changes did not differ by treatment group. There was
also a tendency for the ASOX group to exhibit greater losses in visceral fat,
and the absolute level of visceral fat in this group was significantly lower at
3 months than in the TE and PL groups. There were significant main effects of
treatment at 3 months on serum T and free T (increased in the TE group and
decreased in the ASOX group) and on thyroid hormone parameters (T4 and t3 resin
uptake significantly decreased in the ASOX group compared with the other two
groups). There was a significant decrease in HDL-C, and increase in LDL-C in the
ASOX group, which led to their being switched to the parenteral nandrolone
decanoate (ASND) after 3 months. ASND had opposite effects on visceral fat from
ASOX, producing a significant increase from 3 to 9 months!
while continuing to decrease SQ abdominal fat. ASND treatment also decreased
thigh muscle area, while ASOX treatment increased high muscle. ASND reversed the
effects of ASOX on lipoproteins and thyroid hormones. The previously reported
effect of T to decrease visceral fat was not observed, in fact, visceral fat in
the TE group increased slightly from 3 to 9 months, although SQ fat continued to
decrease. Neither TE nor AS treatment resulted in any change in urologic
parameters.
CONCLUSIONS: Oral oxandrolone decreased SQ abdominal fat more than TE or weight
loss alone and also tended to produce favorable changes in visceral fat. TE and
ASND injections given every 2 weeks had similar effects to weight loss alone on
regional body fat. Most of the beneficial effects observed on metabolic and
cardiovascular risk factors were due to weight loss per se. These results
suggest that SQ and visceral abdominal fat can be independently modulated by
androgens and that at least some anabolic steroids are capable of influencing
abdominal fat.
Oral anabolic steroid treatment, but not parenteral androgen treatment,
decreases abdominal fat in obese, older men.
Lovejoy JC, Bray GA, Greeson CS, Klemperer M, Morris J, Partington C, Tulley R.
Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808-4124, USA.
OBJECTIVE: To compare the effects of testosterone enanthate (TE), anabolic
steroid (AS) or placebo (PL) on regional fat distribution and health risk
factors in obese middle-aged men undergoing weight loss by dietary means.
DESIGN: Randomized, double-blind, placebo-controlled clinical trial, carried out
for 9 months with primary assessments at 3 month intervals. Due to adverse blood
lipid changes, the AS group was switched from oral oxandrolone (ASOX) to
parenteral nandrolone decaoate (ASND) after the 3 month assessment point.
SUBJECTS: Thirty healthy, obese men, aged 40-60 years, with serum testosterone
(T) levels in the low-normal range (2-5 ng/mL).
MAIN OUTCOME MEASURES: Abdominal fat distribution and thigh muscle volume by CT
scan, body composition by dual energy X-ray absorptiometry (DEXA), insulin
sensitivity by the Minimal Model method, blood lipids, blood chemistry, blood
pressure, thyroid hormones and urological parameters.
RESULTS: After 3 months, there was a significantly greater decrease in
subcutaneous (SQ) abdominal fat in the ASOX group compared to the TE and PL
groups although body weight changes did not differ by treatment group. There was
also a tendency for the ASOX group to exhibit greater losses in visceral fat,
and the absolute level of visceral fat in this group was significantly lower at
3 months than in the TE and PL groups. There were significant main effects of
treatment at 3 months on serum T and free T (increased in the TE group and
decreased in the ASOX group) and on thyroid hormone parameters (T4 and t3 resin
uptake significantly decreased in the ASOX group compared with the other two
groups). There was a significant decrease in HDL-C, and increase in LDL-C in the
ASOX group, which led to their being switched to the parenteral nandrolone
decanoate (ASND) after 3 months. ASND had opposite effects on visceral fat from
ASOX, producing a significant increase from 3 to 9 months!
while continuing to decrease SQ abdominal fat. ASND treatment also decreased
thigh muscle area, while ASOX treatment increased high muscle. ASND reversed the
effects of ASOX on lipoproteins and thyroid hormones. The previously reported
effect of T to decrease visceral fat was not observed, in fact, visceral fat in
the TE group increased slightly from 3 to 9 months, although SQ fat continued to
decrease. Neither TE nor AS treatment resulted in any change in urologic
parameters.
CONCLUSIONS: Oral oxandrolone decreased SQ abdominal fat more than TE or weight
loss alone and also tended to produce favorable changes in visceral fat. TE and
ASND injections given every 2 weeks had similar effects to weight loss alone on
regional body fat. Most of the beneficial effects observed on metabolic and
cardiovascular risk factors were due to weight loss per se. These results
suggest that SQ and visceral abdominal fat can be independently modulated by
androgens and that at least some anabolic steroids are capable of influencing
abdominal fat.
Comment